Abstract
Autism spectrum disorder (ASD) is a neurodevelopmental disorder. Autism Spectrum Disorder is diagnosed early on in a child’s life, anywhere from eighteen to twenty-four months. The disorder is characterized by variable degrees, by difficulties in nonverbal communication, verbal communication, social interaction, repetitive behaviors, and movement. The occurrence of ASD has been increasing globally, with the most recent prevalence studies indicating that they are present in six per one thousand children and one in every sixty-eight people of all ages, with a higher incidence among males, with a ratio of four to one. There is no specific target demographic for Autism Spectrum Disorder, nor is there a cure. Over the last few decades, there have been advancements in treating the symptoms associated with Autism Spectrum Disorder. Among the many different fields of research associated with Autism Spectrum Disorder, Bumetanide has shown to be a promising drug therapy for children suffering from Autism, treating specifically the behavioral symptoms associated with ASD. Bumetanide is forty times more potent than furosemide and is a loop diuretic mainly acting in the ascending limb of the loop of Henle. A clinical trial conducted found a decrease in the Childhood Autism Rating Scale (CARS) score, showing improvement in Autism Spectrum Disorder symptoms, such as repetitive behavior and initiating or participating in the social interaction.
Highlights
Over the last few decades, there have been advancements in treating the symptoms associated with Autism Spectrum Disorder
Among the many different fields of research associated with Autism Spectrum Disorder, Bumetanide has shown to be a promising drug therapy for children suffering from Autism, treating the behavioral symptoms associated with Autism spectrum disorder (ASD)
The disorder is characterized by several behavioral nuances such as difficulties in nonverbal communication, verbal communication, social interaction, repetitive behaviors, and movement
Summary
Research of an association between autism and epilepsy implied a biological rather than psychogenic factor in the etiology of autism [3] Individuals suffering from this neurodevelopmental disorder are diagnosed using the Childhood Autism Rating Scale (CARS) [4] [5] [6]. Controlling [Cl−]i can reinstate inhibitory actions of GABA and by doing so open novel therapeutic perspectives in many neurological disorders, such as autism spectrum disorders [30]. Bumetanide can decrease neuronal chloride concentrations and reinstate g-aminobutyric acid (GABA)-ergic inhibition in patients with neurodevelopmental disorders. The excitatory action of GABA on neurons can be reversed by the NKCC1 inhibitor in patients with ASD due to high levels of Cl− in the brain. This review will shed light on autism spectrum disorders, similar diagnoses, the pathophysiology of Bumetanide as treatment, pediatric pharmacokinetics, and wrap it up with a clinical trial overview
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
